A first-in-class antibiotic held its edge against resistant Acinetobacter

Carbapenem-resistant Acinetobacter baumannii (CRAB) sits at the top of the World Health Organization's list of pathogens that most urgently need new drugs, because the ones that survive carbapenems — the antibiotics usually held in reserve — leave clinicians with very little [s2]. A new laboratory study reports that an experimental antibiotic, zosurabalpin, inhibited a large, geographically diverse collection of these bacteria at low concentrations [s1]. It is a promising in-vitro result, and it is important to be clear from the outset that it is only that: activity in a test, not a treatment shown to save patients.

Why CRAB is so hard to treat

A. baumannii is an opportunistic pathogen that causes pneumonia, bloodstream and wound infections, often in intensive care. When it acquires carbapenem resistance — usually through enzymes called carbapenemases carried on mobile pieces of DNA — the remaining options are few and imperfect [s2]. Zosurabalpin is described as a first-in-class tethered macrocyclic-peptide that targets the LptB₂FGC complex, part of the machinery bacteria use to build their outer membrane [s1]. Because that target is different from anything current antibiotics attack, the hope is that existing resistance mechanisms do not apply to it.

What the study did

Researchers tested zosurabalpin against 304 CRAB clinical isolates gathered from six countries — Switzerland, Israel, Turkey, Ethiopia, Pakistan and Australia [s1]. The collection was deliberately weighted toward hard cases: 297 of the isolates carried plasmid-borne carbapenemases, including 236 OXA-type producers, 60 NDM-type producers (alone or combined with OXA enzymes) and one GES-14 producer [s1]. They measured the minimum inhibitory concentration (MIC) — the lowest drug concentration that stops the bacteria growing — and compared it with several drugs used against CRAB today: colistin, cefiderocol, sulbactam-durlobactam and rifabutin [s1].

MIC is the standard yardstick here, and lower is better: a lower MIC means the drug works at a lower concentration. A common summary measure is the MIC90, the concentration that inhibits 90% of the isolates tested.

What it found

Zosurabalpin's MICs ranged from ≤0.032 to 2 mg/L, with an MIC90 of 0.5 mg/L, and no isolate showed MICs suggestive of high-level acquired resistance [s1]. For comparison, the MIC90 values were 8 mg/L for cefiderocol, 16 mg/L for sulbactam-durlobactam, 1 mg/L for colistin and 2 mg/L for rifabutin [s1]. Crucially, the low MICs held even against the metallo-beta-lactamase (NDM) producers that defeat many other agents, and zosurabalpin showed no cross-resistance with any of the drugs tested [s1].

A single isolate stood out with an MIC of 2 mg/L — the top of the range — and it carried a 13-amino-acid deletion in a gene called lptD, which the authors suggest may affect outer-membrane construction and could be an early route to resistance [s1]. That one isolate is the useful caveat: even a drug against a novel target has a way for bacteria to fight back, and the authors say that mechanism should be studied further [s1].

What this does — and does not — show

This is in-vitro surveillance data. It shows that zosurabalpin can inhibit a wide range of CRAB isolates in a dish, which is a genuine and encouraging property [s1]. It does not show that zosurabalpin cures CRAB infections in people, that it is safe at the doses required, or how it compares with existing drugs in a real patient — those questions belong to clinical trials, not MIC plates. The MIC comparisons in this study are also not a head-to-head clinical ranking; they simply report each drug's inhibitory concentration against the same collection of bugs [s1].

It is also worth resisting the language of a "miracle drug". The history of antibiotics is a history of new agents followed, sometimes quickly, by resistance — and this study already found one isolate hinting at how resistance to zosurabalpin might arise [s1]. The value of a new target is that it buys time and options against pathogens that currently have almost none; the emergence of that single lptD variant is a reminder that stewardship will matter for any new drug from its first day of use [s1][s2].

What it means

For now, zosurabalpin is a candidate with an attractive laboratory profile against one of medicine's most stubborn pathogens, not an available treatment. The honest summary is that it inhibited 304 resistant A. baumannii isolates at low concentrations, including strains that evade current drugs, while showing one early sign of how resistance could develop [s1]. Whether that translates into a tool clinicians can actually use will depend on clinical trials of efficacy and safety. This is the early, promising end of the drug pipeline — the part where caution and enthusiasm should travel together.

Sources

• [s1] In vitro activity of zosurabalpin against a global set of carbapenem-resistant A. baumannii clinical isolates. Antimicrobial Agents and Chemotherapy, 16 Sep 2026. https://doi.org/10.1128/aac.00727-26
• [s2] Can we escape from top-priority ESKAPE pathogens? Emerging Microbes & Infections, 19 Jan 2026. https://doi.org/10.1080/22221751.2026.2614739